NovaBridge Biosciences (NBP)
NASDAQ: NBP · Real-Time Price · USD
4.070
+0.080 (2.01%)
At close: Dec 15, 2025, 4:00 PM EST
4.069
-0.002 (-0.04%)
After-hours: Dec 15, 2025, 4:35 PM EST
NovaBridge Biosciences Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
32
Market Cap
469.13M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | - | - | - |
| Dec 31, 2023 | 632.00K | 2.18M | - |
| Dec 31, 2022 | -1.55M | -15.40M | - |
| Dec 31, 2021 | 13.85M | -222.30M | -94.14% |
| Dec 31, 2020 | 236.15M | 231.84M | 5,381.18% |
| Dec 31, 2019 | 4.31M | -3.51M | -44.90% |
| Dec 31, 2018 | 7.82M | 6.04M | 340.20% |
| Dec 31, 2017 | 1.78M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 435.16B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 64.24B |
| AbbVie | 59.64B |
| Eli Lilly and Company | 59.42B |
| AstraZeneca | 58.13B |
| Novartis AG | 56.37B |
| Novo Nordisk | 49.58B |
NBP News
- 5 days ago - NovaBridge Presents Positive Ragistomig Phase 1 Dose Expansion Data at ESMO-IO - GlobeNewsWire
- 12 days ago - NovaBridge Announces Presentation of Ragistomig Expanded Phase 1 Data at ESMO-IO - GlobeNewsWire
- 25 days ago - NovaBridge's Visara Subsidiary Appoints Distinguished Ophthalmology Leaders as Chief Medical Officer and Scientific Advisory Board Chair to Drive VIS-101 Forward - GlobeNewsWire
- 6 weeks ago - NovaBridge Subsidiary Visara Assigns Its Exclusive License to Everest Medicines for VIS-101 in Greater China and Certain Other Asian Countries - GlobeNewsWire
- 6 weeks ago - I-MAB (Nasdaq: IMAB) Transitions to NovaBridge Biosciences (Nasdaq: NBP) with Trading Effective October 30, 2025 New Brand and Logo to Reflect Strategic Transformation to a Global Biotech Platform - GlobeNewsWire
- 7 weeks ago - I-Mab To Present Positive Updated Givastomig Monotherapy Data at 2025 AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Conference on October 23, 2025 - GlobeNewsWire
- 2 months ago - I-Mab (IMAB) Discusses Business Transformation Strategy and Plans for Accelerated Growth Transcript - Seeking Alpha
- 2 months ago - I-Mab Announces Intention to Undertake Strategic Transformation to Global Biotech Platform, to Pursue Hong Kong IPO, and Rebrand as NovaBridge Biosciences - GlobeNewsWire